ReviewCell biochemistry and biophysics2026
Itaconation and Succination as Metabolite-Derived Cysteine Modifications in Inflammatory Signalling: Biochemical Mechanisms, Chemoproteomic Mapping, and Therapeutic Opportunities.
Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory activation rewires cellular metabolism and generates electrophilic metabolites that can modify reactive cysteine residues. This review focuses on two metabolite-derived cysteine modifications: itaconation, driven by aconitate decarboxylase 1 (ACOD1)-dependent itaconate production, and succination, driven by fumarate accumulation. Although both involve cysteine engagement, they differ in chemical stability, metabolite source, cellular distribution, glutathione competition, and functional outcome. Itaconation is linked to Kelch-like ECH-associated protein 1 (KEAP1)-nuclear factor erythroid 2-related factor 2 (NRF2) signalling, glycolytic control, kinase regulation, innate immune sensing, interferon responses, and inflammatory cell death, whereas succination is most strongly associated with stable S-(2-succino)cysteine (2SC) formation, fumarate excess, mitochondrial dysfunction, redox stress, inflammasome regulation, and pyroptosis. A central theme of this review is that endogenous itaconate and fumarate must be distinguished from electrophilic derivatives such as 4-octyl itaconate, dimethyl itaconate, and dimethyl fumarate, because these compounds differ in uptake, reactivity, target engagement, and pharmacological interpretation. We distinguish direct adduct mass spectrometry from competitive cysteine profiling and metabolite-mapping approaches, which can quantify bulk adduct burden, relative cysteine engagement, metabolite distribution, or compartment-specific cysteine state, but do not necessarily establish endogenous site occupancy. Proteomic and chemoproteomic approaches can prioritise metabolite-responsive cysteines, but functional relevance requires site-level validation, residue perturbation, and biochemical rescue. By comparing itaconation and succination across chemistry, target selection, inflammatory signalling, and therapeutic translation, this review defines the evidence needed to identify metabolite-sensitive cysteines as genuine regulatory nodes rather than detectable covalent adducts.
Indexed as
Identifiers
42776374What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.